A free glossary of oncology-related terms and resource organizations.
Why use a resource like nm|OK?
Unlike reports that are 'dead on arrival' nm|OK is a constantly updated comprehensive report on every aspect of oncology drug development. click
Drugs profiled in nm|OK
nm|OK profiles over 4,310 drugs/in vivo imaging agents in development:
3,653 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 have been or are currently being evaluated in clinical trials and 539 of these are targeted agents.
757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.)
nm|OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials.
In vitro testing (IVT) products
nm|OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology.
Enabling technologies/drug delivery
nm|OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc.
Targets in oncology
nm|OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers.
Shorthanded? Need a cost-effective way to monitor developments in oncology. New Medicine provides numerous services:
Need an update on certain items in nm|OK? click
Need to access certain records/saved searches on a routine basis? click
Require more in-depth reports on certain developments in oncology? click
Would your oncology effort benefit from an in-house resource like nm|OK that allows you to combine nm|OK with secure proprietary data? click
The headlines below refer to selected records among the hundreds updated in nm|OK within a 30-day period. A summary of the updated information, the complete records for each item on the list, and numerous other updated entries are available to subscribers upon logging in. Samples of records from each module are here.
Special reports are reviews of current developments of oncology and related drugs by indication, mechanism, delivery technology, etc. as well as personalized medicine, including biomarkers, diagnostics, theragnostics, prognostics, -pharmacogenomics, disease monitoring tests, etc. Samples of special reports are here.
Venetoclax ABT-199, GDC-0199, RG7601
C-ros oncogene 1, receptor tyrosine kinase (ROS1)
Egl-9 family hypoxia-inducible factor 1 (EGLN1)
AbbVie to Submit Venetoclax for Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) Harboring the 17p Deletion
In August 2015, AbbVie reported that, according to an independent review analysis, a phase II clinical trial (protocol ID: M13-982; 2012-004027-20; NCT01889186) with venetoclax met its primary endpoint of ORR in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with the 17p deletion. This open label trial evaluated the efficacy and safety of venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, being developed in partnership with Genentech and Roche. Data from this trial will be presented at an upcoming medical conference and will serve as the pivotal registration data to be submitted to the FDA and the European Medicines Agency (EMA) before the end of 2015. (more...)
FDA’s ODAC Backs Lilly’s Necitumumab BLA for the Treatment of Metastatic Squamous NSCLC
In July 2015, the majority of the members of an FDA ODAC panel agreed that necitumumab provides some benefits for the treatment of locally advanced or metastatic (Stage IV) squamous non-small cell lung cancer (nsclc) despite safety concerns over the potentially increased risk of thrombolytic events. In clinical trials, median OS with necitumumab improved survival by an average 1.6 months, which was statistically significant, and PFS by 0.2 months. However, an FDA briefing document had raised safety concerns regarding the incidence of thromboembolic events. (more...)
The Ultimate Personalized Cancer Therapy? Cancer Vaccines Targeting Neoantigens in a Given Patient’s Tumors
Tumor-specific antigens (neoantigens) derived from mutated proteins that are present only in a given patient’s tumors appear to represent a promising new immunotherapy approach (Hacohen N, et al., Cancer Immunol Res, Jul 2013;1(1):11-5 and Fritsch EF, et al., Oncoimmunology, 25 Jun 2014;3:e29311). These vaccines target the unique immunogenic mutations present in each patient’s tumor, thus marshaling the immune system against a very specific offender. (more...)
Metformin in Combination with Plk1 Inhibitor BI2536 in the Treatment of Hormone-refractory Prostate Cancer
There is increasing evidence that the antidiabetic metformin exerts strong antineoplastic effects on numerous tumor types, including prostate cancer. Additionally, it helps to lower the risk of developing castration-resistant prostate cancer. Investigators at Purdue University (West Lafayette, IN) and colleagues report that inhibition of polo-like kinase 1 (Plk1) with BI2536 enhances the antineoplastic activity of low dose metformin in prostate cancer in vitro and in vivo. Overexpression of Plk1 can trigger the synthesis of androgen. BI2536, a specific Plk1 inhibitor, acts synergistically with metformin in inhibiting prostate cancer cell proliferation and also renders prostate cancer cells harboring wild type p53 much more sensitive to treatment with low dose metformin. The combination of BI2536 and metformin induced p53-dependent apoptosis and further activated the p53/Redd-1 pathway. (more...)
England's National Cancer Drugs Fund Removes 25 Cancer Indications Involving 16 Separate Drugs from its FY16 Covered List
In January 2015, the CDF removed 25 cancer treatment indications involving 16 separate agents from its annual funding list beginning on March 15, 2015. The fund exceeded its budget by ~ £100 million in FY15. This decision eliminates ~ £80 million ($121.3 million) from the FY16 budget for these indications which is nevertheless increased to £340 million in FY16, with its mandate ending on March 15, 2016. In addition the CDF rejected outright another 33 indications involving 19 separate approved anticancer agents. The CDF covered list now includes 62 approved indications. The most telling aspect of the removals is the incredible variety of highly specific indications, some approved and others off label, associated with these drugs that illustrate the complexity of this disease. In addition to the basic cancer type, the clinical indications specify disease stage, biomarker expression, line of treatment often specifying previous exposure by agent, performance status, distinct agent combinations, etc. Each of these specific indications has been evaluated in clinical trials providing the regulators with base line information as to their cost effectiveness. (more...)
Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer
The success of Avastin, an antiangiogenesis agent targeting the VEGF pathway, has prompted the development of numerous similarly acting agents. Avastin, with global revenues of $6,210.5 million in fiscal 2010, is the most commercially successful anticancer drug ever to reach the market. Future Oncology has published a review of VEGF inhibition in the treatment of cancer. (more...)
Future Oncology Archives
Subscribers to New Medicine's Oncology KnowledgeBASE (nm|OK), log in to access the version providing active links to nm|OK records.